The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target

Future Virology

Volumn 10, Issue 5, 2015, Pages 537-546

  Madara, Jonathan J ^a   Han, Ziying ^a   Ruthel, Gordon ^a   Freedman, Bruce D ^a   Harty, Ronald N ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

Author keywords

antiviral; CTD; Ebola; ESCRT; filovirus; L domain; NTD; oligomerization; therapeutic agent; viral budding; virus like particles; VLPs; VP40

Indexed keywords

ESCRT PROTEIN; PROTEIN VP40;

EBOLAVIRUS; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; VIRION; VIRUS ASSEMBLY; VIRUS PARTICLE;

EBOLA VIRUS; MARBURGVIRUS;

EID: 84930345554     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.15.6     Document Type: Review

References (86)

1. Bukreyev AA, Chandran K, Dolnik O et al. Discussions and decisions of the 2012-2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012-June 2013. Arch. Virol. 159(4), 821-830 (2014
2. Team WER. Ebola virus disease in West Africa - the first 9 months of the epidemic and forward projections. N. Engl. J. Med. 371(16), 1481-1495 (2014
3. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol. Med. 12(5), 206-215 (2006
4. Takada A, Kawaoka Y. The pathogenesis of Ebola hemorrhagic fever. Trends Microbiol. 9(10), 506-511 (2001
5. Kreuels B, Wichmann D, Emmerich P et al. A case of severe Ebola virus infection complicated by Gram-negative septicemia. N. Engl. J. Med. 371(25), 2394-2401 (2014
6. ProMed Mail. PRO/AH/EDR Ebola virus disease - West Africa (196): WHO, Mali conf. case ex Guinea, Liberia (Promed Mail Post, 2014-2010-24 00: 49: 04). http://promedmail.org
7. Wolz A. Face to face with Ebola - an emergency care center in Sierra Leone. N. Engl. J. Med. 371(12), 1081-1083 (2014
8. Stahelin RV. Could the Ebola virus matrix protein VP40 be a drug target?. Expert Opin. Ther. Targets 18(2), 115-120 (2014
9. Mehedi M, Falzarano D, Seebach J et al. A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J. Virol. 85(11), 5406-5414 (2011
10. Adu-Gyamfi E, Soni SP, Xue Y, Digman MA, Gratton E, Stahelin RV. The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J. Biol. Chem. 288(8), 5779-5789 (2013
11. Han Z, Boshra H, Sunyer JO, Zwiers SH, Paragas J, Harty RN. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J. Virol. 77(3), 1793-1800 (2003
12. Noda T, Halfmann P, Sagara H, Kawaoka Y. Regions in Ebola virus VP24 that are important for nucleocapsid formation. J. Infect. Dis. 196(Suppl. 2), S247-S250 (2007
13. Watanabe S, Noda T, Halfmann P, Jasenosky L, Kawaoka Y. Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J. Infect. Dis. 196(Suppl. 2), S284-S290 (2007
14. Mateo M, Carbonnelle C, Martinez MJ et al. Knockdown of Ebola virus VP24 impairs viral nucleocapsid assembly and prevents virus replication. J. Infect. Dis. 204(Suppl. 3), S892-S896 (2011
15. Zhang AP, Bornholdt ZA, Liu T et al. The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog. 8(2), e1002550 (2012
16. Watt A, Moukambi F, Banadyga L et al. A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivity. J. Virol. 88(18), 10511-10524 (2014
17. Carette JE, Raaben M, Wong AC et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477(7364), 340-343 (2011
18. Côté M, Misasi J, Ren T et al. Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477(7364), 344-348 (2011
19. Wilson JA, Bray M, Bakken R, Hart MK. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology 286(2), 384-390 (2001
20. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196(Suppl. 2), S430-S437 (2007
21. Warren TK, Warfield KL, Wells J et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 16(9), 991-994 (2010
22. Warren TK, Warfield KL, Wells J et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob. Agents Chemother. 54(5), 2152-2159 (2010
23. Basu A, Li B, Mills DM et al. Identification of a small-molecule entry inhibitor for filoviruses. J. Virol. 85(7), 3106-3119 (2011
24. Iversen PL, Warren TK, Wells JB et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4(11), 2806-2830 (2012
25. Madrid PB, Chopra S, Manger ID et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS ONE 8(4), e60579 (2013
26. Warren TK, Wells J, Panchal RG et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508(7496), 402-405 (2014
27. Ansari AA. Clinical features and pathobiology of Ebola virus infection. J. Autoimmun. 55, 1-9 (2014
28. Marzi A, Feldmann H, Geisbert TW, Falzarano D. Vesicular stomatitis virus-based vaccines for prophylaxis and treatment of filovirus infections. J. Bioterror Biodef. S1(4) (2011
29. Marzi A, Engelmann F, Feldmann F et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc. Natl Acad. Sci. USA 110(5), 1893-1898 (2013
30. Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev. Vaccines 13(4), 521-531 (2014
31. Qiu X, Wong G, Audet J et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514(7520), 47-53 (2014
32. Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs 27(6), 565-583 (2013
33. Timmins J, Scianimanico S, Schoehn G, Weissenhorn W. Vesicular release of ebola virus matrix protein VP40. Virology 283(1), 1-6 (2001
34. Adu-Gyamfi E, Digman MA, Gratton E, Stahelin RV. Investigation of Ebola VP40 assembly and oligomerization in live cells using number and brightness analysis. Biophys. J. 102(11), 2517-2525 (2012
35. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Proc. Natl Acad. Sci. USA 97(25), 13871-13876 (2000
36. Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res. 39(2-3), 129-150 (1995
37. Noda T, Sagara H, Suzuki E, Takada A, Kida H, Kawaoka Y. Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J. Virol. 76(10), 4855-4865 (2002
38. Bornholdt ZA, Noda T, Abelson DM et al. Structural rearrangement of Ebola virus VP40 begets multiple functions in the virus life cycle. Cell 154(4), 763-774 (2013
39. Bukreyev AA, Volchkov VE, Blinov VM, Netesov SV. The VP35 and VP40 proteins of filoviruses. Homology between Marburg and Ebola viruses. FEBS Lett. 322(1), 41-46 (1993
40. Licata JM, Simpson-Holley M, Wright NT, Han Z, Paragas J, Harty RN. Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J. Virol. 77(3), 1812-1819 (2003). L-domain motifs in EBOV VLP assembly and budding
41. Timmins J, Schoehn G, Kohlhaas C, Klenk HD, Ruigrok RW, Weissenhorn W. Oligomerization and polymerization of the filovirus matrix protein VP40. Virology 312(2), 359-368 (2003
42. Jasenosky LD, Kawaoka Y. Filovirus budding. Virus Res. 106(2), 181-188 (2004
43. Yamayoshi S, Kawaoka Y. Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles. J. Infect. Dis. 196(Suppl. 2) S291-S295 (2007
44. Liu Y, Cocka L, Okumura A, Zhang YA, Sunyer JO, Harty RN. Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of viruslike particles. J. Virol. 84(5), 2294-2303 (2010
45. Urata S, Noda T, Kawaoka Y, Morikawa S, Yokosawa H, Yasuda J. Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J. Virol. 81(9), 4895-4899 (2007
46. Mittler E, Kolesnikova L, Herwig A, Dolnik O, Becker S. Assembly of the Marburg virus envelope. Cell. Microbiol. 15(2), 270-284 (2013
47. Stahelin RV. Membrane binding and bending in Ebola VP40 assembly and egress. Front. Microbiol. 5, 300 (2014
48. Dessen A, Volchkov V, Dolnik O, Klenk HD, Weissenhorn W. Crystal structure of the matrix protein VP40 from Ebola virus. EMBO J. 19(16), 4228-4236 (2000
49. Jasenosky LD, Neumann G, Lukashevich I, Kawaoka Y. Ebola virus VP40-induced particle formation and association with the lipid bilayer. J. Virol. 75(11), 5205-5214 (2001
50. Gomis-Rüth FX, Dessen A, Timmins J et al. The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure 11(4), 423-433 (2003
51. McCarthy SE, Johnson RF, Zhang YA, Sunyer JO, Harty RN. Role for amino acids 212KLR214 of Ebola virus VP40 in assembly and budding. J. Virol. 81(20), 11452-11460 (2007
52. Panchal RG, Ruthel G, Kenny TA et al. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl Acad. Sci. USA 100(26), 15936-15941 (2003
53. Adu-Gyamfi E, Digman MA, Gratton E, Stahelin RV. Single-particle tracking demonstrates that actin coordinates the movement of the Ebola virus matrix protein. Biophys. J. 103(9), L41-L43 (2012
54. Lu J, Qu Y, Liu Y et al. Host IQGAP1 and Ebola virus VP40 interactions facilitate virus-like particle egress. J. Virol. 87(13), 7777-7780 (2013
55. Soni SP, Adu-Gyamfi E, Yong SS, Jee CS, Stahelin RV. The Ebola virus matrix protein deeply penetrates the plasma membrane: an important step in viral egress. Biophys. J. 104(9), 1940-1949 (2013
56. Weissenhorn W. Oligomerization and polymerization of the filovirus matrix protein VP40. Virology 312(2), 359-368 (2003
57. Hoenen T, Volchkov V, Kolesnikova L et al. VP40 octamers are essential for Ebola virus replication. J. Virol. 79(3), 1898-1905 (2005
58. Huang M, Orenstein JM, Martin MA, Freed EO. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69(11), 6810-6818 (1995
59. Irie T, Licata JM, Harty RN. Functional characterization of Ebola virus L-domains using VSV recombinants. Virology 336(2), 291-298 (2005
60. Yasuda J, Nakao M, Kawaoka Y, Shida H. Nedd4 regulates egress of Ebola virus-like particles from host cells. J. Virol. 77(18), 9987-9992 (2003
61. Silvestri LS, Ruthel G, Kallstrom G et al. Involvement of vacuolar protein sorting pathway in Ebola virus release independent of TSG101 interaction. J. Infect. Dis. 196(Suppl. 2), S264-S270 (2007
62. Adu-Gyamfi E, Soni SP, Jee CS, Digman MA, Gratton E, Stahelin RV. A Loop region in the N-terminal domain of Ebola virus VP40 is important in viral assembly, budding, and egress. Viruses 6(10), 3837-3854 (2014
63. Miao B, Skidan I, Yang J et al. Small molecule inhibition of phosphatidylinositol-3, 4, 5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc. Natl Acad. Sci. USA 107(46), 20126-20131 (2010
64. Soni SP, Stahelin RV. The Ebola virus matrix protein VP40 selectively induces vesiculation from phosphatidylserine-enriched membranes. J. Biol. Chem. 289(48), 33590-33597 (2014
65. Radzimanowski J, Effantin G, Weissenhorn W. Conformational plasticity of the Ebola virus matrix protein. Protein Sci. 23(11), 1519-1527 (2014
66. Hoenen T, Biedenkopf N, Zielecki F et al. Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription. J. Virol. 84(14), 7053-7063 (2010
67. Alfadhli A, McNett H, Eccles J et al. Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site. J. Biol. Chem. 288(1), 666-676 (2013
68. Beth McDonald JM-S. No strings attached: the ESCRT machinery in viral budding and cytokinesis. J. Cell. Sci. 122(Pt 13), 2167-2177 (2009
69. Li Z, Tian H, Liu T. Cellular ESCRT complex and its roles in enveloped viruses budding. Sheng Wu Gong Cheng Xue Bao 28(9), 1031-1037 (2012
70. Votteler J, Sundquist WI. Virus budding and the ESCRT pathway. Cell Host Microbe 14(3), 232-241 (2013
71. Neumann G, Ebihara H, Takada A et al. Ebola virus VP40 late domains are not essential for viral replication in cell culture. J. Virol. 79(16), 10300-10307 (2005
72. Lu J, Han Z, Liu Y et al. A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress. J. Virol. 88(9), 4736-4743 (2014
73. Han Z, Lu J, Liu Y et al. Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. J. Virol. 88(13), 7294-7306 (2014
74. Chen BJ, Lamb RA. Mechanisms for enveloped virus budding: can some viruses do without an ESCRT?. Virology 372(2), 221-232 (2008
75. Ehrlich LS, Carter CA. HIV assembly and budding: Ca(2+) signaling and non-ESCRT proteins set the stage. Mol. Biol. Int. doi: 10.1155/2012/851670 851670 (2012
76. Teis SA. The ESCRT machinery. Science 22(4), R116-R120 (2012
77. Pornillos O, Garrus JE, Sundquist WI. Mechanisms of enveloped RNA virus budding. Trends Cell Biol. 12(12), 569-579 (2002
78. Zhai Q, Fisher RD, Chung HY, Myszka DG, Sundquist WI, Hill CP. Structural and functional studies of ALIX interactions with YPX(n)L late domains of HIV-1 and EIAV. Nat. Struct. Mol. Biol. 15(1), 43-49 (2008
79. Morita E, Sandrin V, McCullough J, Katsuyama A, Baci Hamilton I, Sundquist WI. ESCRT-III protein requirements for HIV-1 budding. Cell Host Microbe 9(3), 235-242 (2011
80. Strack B, Calistri A, Craig S, Popova E, Göttlinger HG. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114(6), 689-699 (2003
81. Weiss ER, Popova E, Yamanaka H, Kim HC, Huibregtse JM, Göttlinger H. Rescue of HIV-1 release by targeting widely divergent NEDD4-type ubiquitin ligases and isolated catalytic HECT domains to Gag. PLoS Pathog. 6(9), e1001107 (2010
82. García M, Cooper A, Shi W et al. Productive replication of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci. Transl. Med. 4(123), 123ra124 (2012
83. Reid SP, Leung LW, Hartman AL et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80(11), 5156-5167 (2006
84. Halfmann P, Neumann G, Kawaoka Y. The Ebola virus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase. J. Infect. Dis. 204(Suppl. 3), S953-S956 (2011
85. Noda T, Kolesnikova L, Becker S, Kawaoka Y. The importance of the NP: VP35 ratio in Ebola virus nucleocapsid formation. J. Infect. Dis. 204(Suppl. 3), S878-S883 (2011
86. Lu J, Qu Y, Liu Y et al. Host IQGAP1 and Ebola virus VP40 interactions facilitate virus-like particle egress. J. Virol. 87(13), 7777-7780 (2013